3Lichtenstein L, Jaffe HL. Fibrous dysplasia of bone. A condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism still other extra skeletal abnormalities. Arch Pathol, 1942,33:777-816.
4Kaplan FS, Fallon MD, Boden SD, et al. Estrogen receptors in bone in a patient with polyostotic fibrous dysplasia (McCune-Abfight syndrome). N EngI J Med, 1988, 319(7) :421-425.
5Leer AI, Chebli C, Kushner H, et al. Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res,2004, 19(4) :571-577.
6Riminucci M, Collins MT, Fedarko NS, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate. J Clin Invest, 2003, 12(5) :683-692.
7Fukumoto S, Yamashita T. FGF23 is a hormone regulating phosphate metabolism-Unique biological characteristics of FGF23. Bone, 2007, 40(5) : 1190-1195.
8Chapurlat RD, Hugueny P, Delmas PD, et al. Treatment of fibrous dysplasia of bone with intravenous parnidronate : long-term effectiveness and evaluation of predictors of response to treatment. Bone, 2004, 35(1):235-242.
9Kobayashi K, Imanishi Y, Koshiyama H, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Seienees, 2006,78 (20) : 2295-2301.
10Ippolito E, Bray EW, Corsi A, et al. Natural history and treatment of fibrous dysplasia of bone: a multicenter clinicopathologic study promoted by the European Pediatric Orthopaedic Society. J Pediatr Orthop B, 2003, 12(3) : 155-177.
